Dupixent vs Zoryve

There is no titration. The number is fixed by age and weight; the only variable is how often you inject.

Loading dose: Adults start with two 300 mg injections the same day at two different spots — 600 mg total. That front-loading reaches a working level quickly.

Usual dose: 300 mg every two weeks for adults. Adolescents 12 and over who weigh about 60 kg or more use the same schedule.

Children and smaller adolescents: Dose is set by weight, and the youngest children inject every four weeks rather than every two. Go by the prescription.

Going up: There is nothing higher. If it is not working at sixteen weeks, the conversation is about a different treatment, not a bigger dose.

Total course: Open-ended. This is maintenance, not a course — people stay on it for years when it works.

Pick a day of the week and keep it. Take the pen or syringe out of the fridge 30 to 45 minutes ahead and let it warm to room temperature on its own — never in hot water, on a radiator, or in a microwave. A cold injection stings much more, and that one step explains most of the difference between people.

Inject into the front of the thigh or the abdomen, at least two inches from the navel. The upper arm works if someone else is injecting. Change the spot each time and avoid skin that is bruised, tender, scarred, or flaring. If the dose is two injections, give them one after the other in two different spots.

Give it as soon as you remember, as long as that is within about a week of the due day, then go back to your schedule. If longer than that, skip it and take the next on the usual day. Never double up to catch up. One missed injection does not undo months of treatment.

No routine blood tests are required — no liver, kidney, or blood count checks, which is a real advantage over the older systemic eczema drugs. Monitoring is a conversation about the skin, the itch, and the eyes.

Ask about the eyes at every visit. Conjunctivitis affects roughly one in ten people treated for eczema, more often with severe skin or eyelid involvement, and usually responds to lubricating drops or a short prescription course. Eye pain or changed vision goes to an eye doctor rather than being watched. Eosinophil counts rise in some people without causing anything, so a count taken for another reason should be read with that in mind.

Nothing builds up over the years, and there is no ceiling on how long you can stay on it. The recurring problem is insurance renewal, not safety.

First few minutesThe injection: A sting for a few seconds, then redness or aching. Common early, and it settles with later doses.

Weeks 1 to 2Itch lifts: Often within days, before anything shows in the mirror. The earliest and most reliable change.

Weeks 2 to 8Working: Sleep improves, scratching drops, and the skin looks calmer. Red or gritty eyes, if they happen, start here.

Weeks 12 to 16Judge it here: Trials measured their main result at sixteen weeks. Most responders reach their best skin here and a good number get close to clear; people only partly better at twelve often kept improving.

Weeks 12 to 24Sleep and daily life: These follow the itch, on a similar timeline, and trials measured them separately from the rash.

After 6 monthsThe face and neck: A stubborn pink patch appears here in a minority, usually after the rest of the skin has cleared. It is treatable and not a sign the drug has stopped working.

Cost decides access here more often than anything medical. Dupilumab is a biologic with no generic and no biosimilar in the United States, and the list price runs to tens of thousands of dollars a year. Almost nobody pays that, and almost everybody has to do the paperwork that brings it down.

Prior authorization is close to universal. Plans want a diagnosis, a record of how much of the body is affected, and evidence that prescription topicals were tried and could not hold the disease — usually a mid- or high-strength steroid, often a calcineurin inhibitor too. Some add phototherapy or an older systemic drug first. First-pass denials are common and appeals often succeed, so a denial is a step, not the end. Ask the prescribing office who handles appeals.

The manufacturer's copay program cuts the monthly cost sharply for people with commercial insurance, and a separate program covers people with no insurance. Copay cards cannot be used with Medicare, Medicaid, or other government plans, which is where the largest out-of-pocket gaps sit. Terms change every year, so a plan that refused last year is worth asking again.